Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XW003 vs dulaglutide in adults with type 2 diabetes inadequately controlled on metformin
CTR20223157Phase 3Completed
- Sponsor
- Sciwind Biosciences
- Start
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ecnoglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sciwind Biosciences. Primary endpoint: Change in HbA1c from baseline at Week 32. Started Dec 2022; status: completed.
02
Drugs
ecnoglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20223157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223157.